Blenrep (belantamab mafadotin) for multiple myeloma — Dr. Jesus Berdeja | MCRT Webcast August 22

Blenrep (belantamab mafadotin) for multiple myeloma — Dr. Jesus Berdeja | MCRT Webcast August 22

Know Your Myeloma Immunotherapy: Antibody Drug Conjugates with Dr. Jesus BerdejaПодробнее

Know Your Myeloma Immunotherapy: Antibody Drug Conjugates with Dr. Jesus Berdeja

MCRT San Diego 2020: Jesús Berdeja Presentation - ImmunotherapiesПодробнее

MCRT San Diego 2020: Jesús Berdeja Presentation - Immunotherapies

Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myelomaПодробнее

Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myeloma

The promise of belantamab mafodotin for the treatment of multiple myelomaПодробнее

The promise of belantamab mafodotin for the treatment of multiple myeloma

All About BLENREP (Belantamab Mafodotin-blmf)Подробнее

All About BLENREP (Belantamab Mafodotin-blmf)

Dr. Berdeja on Updated CARTITUDE-1 Results With JNJ-4258 in Multiple MyelomaПодробнее

Dr. Berdeja on Updated CARTITUDE-1 Results With JNJ-4258 in Multiple Myeloma

BLENREP (belantamab mafodotin-blmf) Mechanism of Action in Multiple MyelomaПодробнее

BLENREP (belantamab mafodotin-blmf) Mechanism of Action in Multiple Myeloma

Dr. Berdeja on Dosing JNJ-4528 in Relapsed/Refractory Multiple MyelomaПодробнее

Dr. Berdeja on Dosing JNJ-4528 in Relapsed/Refractory Multiple Myeloma

DREAMM-2: Belantamab mafodotin for R/R myelomaПодробнее

DREAMM-2: Belantamab mafodotin for R/R myeloma

Treatment combinations being explored with belantamab mafodotin in multiple myelomaПодробнее

Treatment combinations being explored with belantamab mafodotin in multiple myeloma

Dr. Berdeja on Updated Data With bb21217 in Multiple MyelomaПодробнее

Dr. Berdeja on Updated Data With bb21217 in Multiple Myeloma

Jesus Berdeja, MD, shares design and outcomes of the CARTITUDE-1 trial in multiple myeloma patientsПодробнее

Jesus Berdeja, MD, shares design and outcomes of the CARTITUDE-1 trial in multiple myeloma patients

DREAMM-9 Blenrep + VRd vs VRd in Newly Diagnosed Transplant Ineligible Myeloma | Saad Usmani ASH21Подробнее

DREAMM-9 Blenrep + VRd vs VRd in Newly Diagnosed Transplant Ineligible Myeloma | Saad Usmani ASH21

Belantamab Mafodotin for Multiple Myeloma | NEJMПодробнее

Belantamab Mafodotin for Multiple Myeloma | NEJM

Dr. Berdeja on Treatment of Patients With Newly Diagnosed MyelomaПодробнее

Dr. Berdeja on Treatment of Patients With Newly Diagnosed Myeloma

Managing belantamab mafodotin-associated corneal adverse events in multiple myelomaПодробнее

Managing belantamab mafodotin-associated corneal adverse events in multiple myeloma

DREAMM-2: update on belantamab mafodotin in R/R myelomaПодробнее

DREAMM-2: update on belantamab mafodotin in R/R myeloma

Dr. Lonial on the FDA Approval of Belantamab Mafodotin in Multiple MyelomaПодробнее

Dr. Lonial on the FDA Approval of Belantamab Mafodotin in Multiple Myeloma